Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Atara Biotherapeutics IncATRA-0.361.04-0.66-0.54278.27%-30.74%56.52$9.76$2.09618$10.60

Detail of Atara Biotherapeutics Inc

 
CEO
Dr. Anhco Nguyen Ph.D.
Employees
165
Industry
Biotechnology
Sector
Healthcare
Market cap
$65M

Company details

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OI
OIE
PI
TAX
NI
Revenue (Rev)
$62.39M
Cost of goods (CoG)
-$12.39M
Gross profit (GP)
$50.00M
Operating expense (OE)
-$229.05M
Research and development (R&D)
-$185.33M
General and administrative (G&A)
-$43.73M
Operating income (OI)
-$179.05M
Other income expense (OIE)
-$23,000.00
Pretax income (PI)
-$181.03M
Tax (TAX)
-$16,000.00
Net income (NI)
-$181.05M
Atara Biotherapeutics Inc
ATRA • XNGS • US
$10.60
+9.79 (1,748.21%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$29.47
Margin profit
-290.20%
52 week low
$0.395
52 week high
$14.34
50-day simple moving average
$11.83
200-day simple moving average
$9.76
Percent held by insiders
22.15%
Percent held by institutions
50.82%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
ATRA +1,785.25%
eps change
ATRA 0.00%